Reunion Neuroscience has received FDA clearance to begin a Phase 2 study of RE104, a novel serotonergic psychedelic compound for treating postpartum depression (PPD). The company, which recently went private after listing on NASDAQ, will commence its multicenter, randomized, double-blind, placebo-controlled trial in Q4 2023. The trial will evaluate the safety and efficacy of a single subcutaneous dose of RE104 in adult female patients with PPD. RE104 is protected under U.S. patent No. 11,292,765, but there's an ongoing legal battle over the compound's creative ownership, including a lawsuit filed by Reunion against Mindset Pharma.